KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Shares Outstanding (Weighted Average): 2018-2025

Historic Shares Outstanding (Weighted Average) for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $201.6 million.

  • Esperion Therapeutics' Shares Outstanding (Weighted Average) rose 2.75% to $201.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $201.6 million, marking a year-over-year increase of 2.75%. This contributed to the annual value of $197.0 million for FY2024, which is 73.27% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Shares Outstanding (Weighted Average) of $201.6 million as of Q3 2025, which was up 1.73% from $198.2 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $201.6 million in Q3 2025 and a low of $27.9 million during Q1 2021.
  • For the 3-year period, Esperion Therapeutics' Shares Outstanding (Weighted Average) averaged around $159.8 million, with its median value being $189.5 million (2024).
  • Data for Esperion Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 153.41% (in 2022) over the last 5 years.
  • Esperion Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $29.1 million in 2021, then spiked by 153.41% to $73.7 million in 2022, then soared by 54.33% to $113.7 million in 2023, then spiked by 73.27% to $197.0 million in 2024, then grew by 2.75% to $201.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $201.6 million in Q3 2025, compared to $198.2 million in Q2 2025 and $197.8 million in Q1 2025.